[CALA] Calithera Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.5 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CALA

Refresh chart

Strongest Trends Summary For CALA

CALA is in the medium-term down -20% below S&P in 1 year and down -50% below S&P in 1 year. In the long-term down -84% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-8.67
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.57% ROE-21.41% ROI
Current Ratio25.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-20.47 M Cash From Operating Activities-7.63 M Gross Profit
Net Profit-7.86 M Operating Profit-7.87 M Total Assets96.87 M Total Current Assets90.31 M
Total Current Liabilities3.52 M Total Debt Total Liabilities3.77 M Total Revenue
Technical Data
High 52 week6.75 Low 52 week2.52 Last close2.6 Last change1.96%
RSI26.01 Average true range0.26 Beta1.45 Volume180.6 K
Simple moving average 20 days-15.61% Simple moving average 50 days-28.08% Simple moving average 200 days-46.18%
Performance Data
Performance Week-4.41% Performance Month-36.59% Performance Quart-39.53% Performance Half-59.25%
Performance Year-59.06% Performance Year-to-date-42.22% Volatility daily4.51% Volatility weekly10.1%
Volatility monthly20.69% Volatility yearly71.67% Relative Volume2060.39% Average Volume340.44 K
New High New Low

News

2020-06-02 07:00:10 | Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-29 08:00:10 | Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting

2020-05-27 07:01:10 | Calithera to Present at the Jefferies Virtual Healthcare Conference

2020-05-18 11:30:03 | Has Calithera Biosciences CALA Outpaced Other Medical Stocks This Year?

2020-05-13 09:15:01 | Is Calithera Biosciences CALA Stock a Solid Choice Right Now?

2020-05-11 12:00:04 | What Makes Calithera CALA a New Buy Stock

2020-05-08 16:27:35 | Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT

2020-05-08 13:01:54 | Calithera Biosciences Inc CALA Q1 2020 Earnings Call Transcript

2020-05-07 16:05:10 | Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights

2020-05-06 07:05:10 | Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635c4

2020-05-01 09:57:05 | Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

2020-04-30 07:01:10 | Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

2020-04-20 16:05:10 | Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

2020-04-16 00:18:32 | Calithera Biosciences, Inc. Prices Public Offering of 5,000,000 shares of Common Stock

2020-04-15 16:01:10 | Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

2020-04-14 08:48:12 | Calithera CALA Soars: Stock Adds 9.4% in Session

2020-04-14 07:00:10 | Calithera Biosciences Provides Update on Business Operations

2020-04-13 11:14:00 | How to Play Speculative Calithera Biosciences

2020-04-07 09:30:15 | Billionaire Steven Cohen Picks up These 2 Stocks on the Dip

2020-03-28 09:09:40 | Have Insiders Been Buying Calithera Biosciences, Inc. NASDAQ:CALA Shares?

2020-03-12 03:00:11 | Edited Transcript of CALA earnings conference call or presentation 11-Mar-20 9:00pm GMT

2020-03-11 16:10:10 | Calithera Biosciences Reports Fourth Quarter 2019 Financial Results and Recent Highlights

2020-03-11 15:00:00 | Calithera Biosciences, Inc. to Host Earnings Call

2020-03-04 07:05:10 | Calithera Biosciences to Report Fourth Quarter 2019 Financial Results on Wednesday, March 11, 2020

2020-02-19 07:05:10 | Calithera to Participate in the 9th Annual SVB Leerink Global Healthcare Conference

2020-01-30 09:38:05 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Paid Enough Relative To Peers?

2020-01-13 07:07:10 | Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

2020-01-03 07:05:10 | Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-12-13 14:46:42 | Hedge Funds Are Dumping Calithera Biosciences Inc CALA

2019-12-06 07:05:10 | Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

2019-12-05 07:05:10 | Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-12-02 11:38:03 | Imagine Owning Calithera Biosciences NASDAQ:CALA While The Price Tanked 64%

2019-11-23 08:36:35 | Edited Transcript of CALA earnings conference call or presentation 12-Nov-19 10:00pm GMT

2019-11-12 16:06:00 | Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

2019-11-05 08:01:00 | Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer SITC Annual Meeting

2019-11-04 08:00:00 | Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

2019-10-19 09:23:18 | Read This Before Selling Calithera Biosciences, Inc. NASDAQ:CALA Shares

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study

2019-10-03 07:05:00 | Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

2019-10-01 16:05:00 | Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer SITC Annual Meeting

2019-09-29 10:30:00 | New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

2019-09-28 02:30:00 | Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

2019-09-27 09:28:01 | Calithera Biosciences Enters Oversold Territory

2019-09-26 18:05:00 | Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology ESMO Congress 2019

2019-09-26 12:00:04 | Implied Volatility Surging for Calithera CALA Stock Options

2019-09-25 08:05:00 | Calithera to Present at the 2019 Cantor Global Healthcare Conference

2019-09-19 10:06:40 | Calithera Biosciences, Inc. NASDAQ:CALA: Is It Growing Too Fast?

2019-08-28 08:00:00 | Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?